Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar

By sjmartinez • July 5, 2022

Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022 Jul 5;66:104025. doi: 10.1016/j.msard.2022.104025. Epub ahead of print. PMID: 36007339.

All clinical trials, All demyelinating disease (CNS), Autoimmune diseases, Devic's syndrome, Neuromyelitis optica spectrum disorder, Patient safety,

Tags: Digestive Diseases, Publications

Related Posts

Corrigendum to “Subchronic inhalation exposure to ultrafine particulate matter alters the intestinal microbiome in various mouse models” [Environ. Res. 248 (2024) 118242]

Chang C, Gupta R, Sedighian F, Louie A, Gonzalez DM, Le C, Cho JM, Park SK, Castellanos J, Ting TW, Dong TS, Arias-Jayo N, Lagishetty[...]

Effectiveness of transoral endoscopic fundoplication with or without hiatal hernia repair in patients with gerd and chronic cough

Swei E, Almario JA, Dunbar K, Yadlapati R, Parker B, Brewer-Gutierrez O, Janu P, Murray M, Sohagia A, Diehl DL, Khara H, Abu Dayyeh B,[...]

Identification of a PRDM1-regulated T cell network to regulate atherosclerotic plaque inflammation

Jin H, Maas SL, Zou Y, Lu C, Yu B, Huchzermeier R, Nadeau S, Dos Santos J, Gijbels M, Mees BME, Smirnov E, Matic L,[...]